Clinical Trial Expert’s Deep Dive Into The Important New Liraglutide Trial

–Sanjay Kaul plunges into the LEADER data pool There will be a lot of discussion in the near future about the LEADER trial, the large new trial assessing cardiovascular outcomes with liraglutide (Victoza, Novo Nordisk). The trial is the latest in a series of large CVOTs with new diabetes drugs showing benefit— or at least...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Diabetes People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes CVOT LEADER liraglutide Victoza Source Type: blogs